

Funds Management

### Monthly update: 31 October 2020

# **Celeste Australian Small Companies Fund**

#### Performance Statistics (Total Returns net of fees)

1	mth %	1 yr %	3 yrs % p.a.	5 yrs % p.a.	10 yrs % p.a.	15 yrs % p.a.
Celeste Aust. Small Co. Fund	+0.5	-1.3	+4.6	+8.4	+5.5	+7.1
Performance (relative to Index)	0.0	+1.1	0.0	-0.2	+2.3	+3.3
S&P/ASX Small Ords Acc Index	+0.5	-2.4	+4.6	+8.6	+3.2	+3.8
S&P/ASX Small Inds Acc Index	+0.6	-3.6	+4.9	+7.5	+7.8	+4.8
S&P/ASX Small Res Acc Index	-0.2	+2.6	+3.5	+13.8	-7.5	+0.9

Past performance is not indicative of future returns. Total returns shown for the Celeste Australian Small Companies Fund has been calculated using exit prices after taking into account all of the Fund's ongoing fees and assuming reinvestment of distributions. No allowance has been made for entry fees or taxation.

#### **Portfolio Commentary**

The Fund rose 0.5%<sup>1</sup> in October, with its benchmark, the S&P/ASX Small Ordinaries Accumulation Index also increasing by 0.5%. Since inception (May 1998) the Fund's return is 12.7% pa<sup>1</sup>, net of all fees, against the Index's 5.6% pa.

On the back of a strong first quarter, where EBITA was up 21% on pcp, **Steadfast** (SDF), raised FY21 EPS growth guidance to 10-15% from 5-10%. Despite the broader economy being impacted by the Covid-19 pandemic, SDF's operations have proven resilient: Insurance broking volumes are holding firm while premium rates have continued to increase; Underwriting Agencies have delivered strong organic growth; and expense savings have been delivered across the group.

**Bapcor** (BAP) reported a strong start to the new financial year, with group revenue up 27% for 1Q21 vs pcp. All areas of the Bapcor group performed well during the period, with the standout being the Retail operations, Autobam, reporting same store sales growth of 36%. Bapcor's core division, Burson Trade, also witnessed strong growth with same store sales up 7.7% nationally and up 17% excluding Victoria. Although we expect these growth rates to moderate over the medium term, the underlying resilience of the Bapcor business model continues to produce stronger cash flows than the market has anticipated.

**WPP AUNZ** (WPP) performed strongly in October, with the share price up 20%. During the month, the company provided a trading update for the September quarter. Despite net sales continuing to be impacted by weak economic activity, ongoing cost cutting resulted in EBIT of \$24.6m for the quarter, which was \$3.3m or 15.4% ahead of the September quarter in 2019. In our opinion much of the cost cutting measures taken by WPP in 2020 are sustainable and will lead to improved levels of profitability as the broader economy recovers from the impact of the Covid-19 pandemic.

Over the month we initiated a small position in **Clover Corporation** (CLV), an IP heavy business that manufacturers DHA (essential fatty acids) added to baby formula and other food related products. The October selloff in CLV was driven by Covid-19 destocking lowering 1h21 earnings expectations. We expect strong volume, revenue and profit growth over the medium term driven by increased demand for DHA from legislation changes in the EU & China, increased UHT production in the US and higher profit margins driven by a new manufacturing facility.

#### **Portfolio Top 5 Holdings**

Stock	% of Fund
1 CODAN	4.3
2 ARB CORPORATION	4.1
3 STEADFAST GROUP	3.9
4 BREVILLE GROUP	3.8
5 EAGERS AUTOMOTIVE	3.7

#### **Global Index Performance (Accumulation)**

	1 month %	1 year %	3 years % pa		
Australia – S&P/ASX All Ordinaries	+2.1	-6.5	+4.8		
USA-S&P 500	-2.8	+7.7	+8.3		
USA – NASDAQ Composite	-2.3	+31.6	+17.5		
Europe – FTSE (UK)	-4.9	-23.1	-9.4		
Europe – DAX (Germany)	-9.4	-10.2	-4.4		
Asia – Nikkei (Japan)	-0.9	+0.2	+1.4		
Asia – Shanghai Composite (China)	+0.2	+10.1	-1.7		

Source: IRESS

#### **Market Commentary**

Equity markets in October were extremely volatile with the Small Ords up more than 5% early in the month post a positive Federal Budget and lower Covid-19 cases in Victoria. By month end most of the early gains had been given up as the US and Europe began to discuss reinstating lockdowns in response to a staggering increase in the number of Covid-19 infections. The Small Ords underperformed the ASX100 by 175bp in October, which was driven by strong performance in both IT and financial stocks.

The Commonwealth Budget delivered significant stimulus (tax cuts, JobMaker, Infrastructure spending & business asset write-offs) with the 20/21 budget balance now a record deficit of \$214bn. At 11% of GDP it remains the largest deficit since WWII. If one were to aggregate the additional state based stimulus this would total \$343bn or some 17% of GDP. This compares to a global average stimulus of around 5% of GDP. While the RBA left policy settings unchanged in October, they cut on the 3<sup>rd</sup> November to provide additional monetary policy support for economic growth. AGM season gave little forward guidance given ongoing uncertainty around lockdowns and the roll off of government support.

The US election reached a crescendo despite the President testing positive for Covid-19 and causing disruption to the closing stages of the campaign. Polling would seem to suggest that it is likely a Biden White House will also deliver a Democratic clean sweep of the House of Representatives and the Senate. It will not however deliver the appointment of the 9<sup>th</sup> Justice to the US Supreme Court with a candidate confirmed on 26<sup>th</sup> October 2020, 8 days prior to the election. Market concern remains focused on large scale civil unrest post the result on 3<sup>rd</sup> November. In response to higher levels of uncertainty the US 10 year bond yield rose sharply in October by 17bp to 85bp.

Globally Covid-19 cases skyrocketed with Europe entering a second wave. France, Germany, Italy, Spain and the UK re-entered nationwide partial or full mobility restrictions in an attempt to limit hospitalisations. The US entered a 3<sup>rd</sup> wave and continues to see no real coordinated response around lockdowns or cohesive mitigation strategies. The speed of infections continues to dampen markets which had been more focused on the medium term delivery of a vaccine and a reversion back to a more normal environment.

With the future path to economic recovery dependent on both Covid19 containment and the discovery of a vaccine, we expect equity markets to display elevated levels of volatility in the short term. We acknowledge that the level of current fiscal and monetary stimulus creates an economic backdrop that is unprecedented, and highly accommodative. We maintain a cautious disposition given broader equity market valuations, and will look to add to the portfolio in a process consistent manner, when valuations are appropriately compelling.



Monthly update: 31 October 2020


## Fund at a Glance

Fund Information

Fund Information			
Primary Investments	Shares in listed Australian smaller companies		
Investment objective	Exceed Small Ordinaries Accumulation Index over rolling 5 year periods		
Unit price (redemption) as at 31.10.2020	\$3.6206		
Unit price (application) as at 31.10.2020	\$3.6424		
Fund Size as at 31.10.2020	\$68m		
Minimum investment	\$25,000		
Minimum additional investment	\$1,000		
Minimum balance	\$15,000		
Redemption will generally be available in	7 days		
Distributions	30 June and 31 December		
Entry fee*	0%		
Exit fee*	0%		
Buy/Sell differential*	0.30%		
Management fee*	1.10% p.a		
Performance fee**	20% of return above benchmark		
* These face and charries apply for the duration of the Directory of Directory in Statement (DDS) and are inclusive of the Coade and Senvices Tax			

\* These fees and charges apply for the duration of the Product Disclosure Statement (PDS) and are inclusive of the Goods and Services Tax. \*\* A fee charged on performance of the investments of the Fund above the nominated benchmark performance. The benchmark is the S&P/ASX Small Ordinaries Accumulation Index.

#### **Fund Returns**



## **Distribution History**

Total distribution year ended					
June 11	11.89	4.6			
June 12	4.07	1.4			
June 13	15.81	5.5			
June 14	14.56	5.4			
June 15	12.67	4.5			
June 16	9.95	4.0			
June 17	6.87	2.6			
June 18	7.01	2.2			
June 19	10.46	2.9			
June 20	9.51	2.8			

Past performance is not indicative of future returns. Total returns shown for the Celeste Australian Small Companies Fund has been calculated using exit prices after taking into account all of the Fund's ongoing fees and assuming reinvestment of distributions. No allowance has been made for entry fees or taxation.

#### \*\* CPU / unit price at beginning of period

Celeste Funds Management Limited ABN 78 098 628 605 (AFSL 222 445) is authorised to provide financial product services to wholesale clients. This report is intended to provide only general securities information and is not to be construed as financial product advice, solicitation of an offer to buy or sell any financial product or a recommendation to buy, sell or hold a particular financial product. Accordingly, reliance should not be placed on this report as the basis for making an investment, financial or other decision. The information in this report does not take into account your investment objectives, financial situation or particular needs. Whilst every effort is taken to ensure the information in this report is accurate, its accuracy, reliability or completeness is not guaranteed.

This report has been issued by The Trust Company (RE Services) Limited ABN 45 003 278 831 (AFSL 235 150) (Perpetual) who is the Responsible Entity of and issuer of units in the Celeste Australian Small Companies Fund (Fund). Celeste Funds Management Limited is the investment manager of the Fund. Retail clients can invest in units in the Fund issued by Perpetual. Perpetual is authorised to deal with retail clients and a product disclosure statement (PDS) issued by Perpetual is available from Celeste Funds Management Limited (02) 9216 1800 or at <u>www.celestefunds.com.au</u>. You should obtain and consider the PDS before deciding whether to acquire, or continue to hold, an interest in the Fund. Initial applications for units in the Fund can only be made pursuant to the application form attached to the PDS. Before making any decision to make or hold any investment in the Fund you should consider the PDS in full. You should consider your own investment objectives, financial situation and particular needs before acting upon any information provided and consider seeking advice from a financial advisor if necessary.

<sup>1</sup> Total returns shown for the Celeste Australian Small Companies Fund has been calculated using exit prices after taking into account all of the Fund's ongoing fees and assuming reinvestment of distributions. No allowance has been made for entry fees or taxation. You should not base an investment decision simply on past performance. Past performance is not an indicator of future performance. Returns are not guaranteed and so the value of an investment may rise or fall.

#### Celeste Funds Management Limited Level 14, 15 Castlereagh Street, Sydney NSW 2000. GPO Box 4266, Sydney NSW 2001 T 02 9216 1800 F 02 9216 1899 E <u>contact@celestefunds.com.au</u> www.celestefunds.com.au